Malanta Ltd and Lightspeed Venture Partners have jointly led a $28 million Series A financing for Luminary Health, the integrated digital healthcare platform serving patients across Sub-Saharan Africa and Southeast Asia. The round closed in February 2025 and represents the first formal co-investment between Malanta and Lightspeed, marking the beginning of what both firms anticipate will be a long-term and productive partnership.
Luminary Health was founded in 2022 by a team with deep roots in both clinical practice and consumer technology. The company's platform integrates telemedicine consultations, diagnostic test coordination, pharmacy fulfilment, and health insurance access into a single mobile-first experience. Today, Luminary Health serves over 2.4 million registered patients across eight countries: Kenya, Nigeria, Ghana, Tanzania, Indonesia, the Philippines, Vietnam, and Bangladesh. The company has experienced exceptional growth, with monthly active users increasing by over 320% in the twelve months preceding the Series A close.
The Partnership Between Malanta and Lightspeed
The co-investment relationship between Malanta and Lightspeed did not emerge from a cold introduction. Both firms had independently identified Luminary Health through their respective emerging market healthcare networks, and came to the opportunity with shared conviction but complementary analytical frameworks. Lightspeed's global healthcare portfolio and its deep relationships within the international development and global health ecosystem brought a specific kind of institutional knowledge and network access to the transaction. Malanta's operational focus and regional presence in the markets Luminary Health operates in provided a different set of capabilities: the ability to support the management team on the ground as they execute their expansion strategy.
Together, we believe we offer Luminary Health's founders something genuinely differentiated. The combination of a global institutional platform with strong US and Indian market relationships, and a growth-focused European fund with hands-on emerging market operational expertise, creates a cap table that the company can leverage in multiple dimensions as it scales. We intend to work as a coordinated partnership rather than competing for board influence or portfolio company attention, and our initial discussions with Luminary Health's management confirm that this kind of collaborative investor relationship is precisely what they were looking for in growth capital partners.
Use of Proceeds and Growth Plan
The $28 million Series A will fund three primary priorities. The first is geographic expansion: Luminary Health intends to launch operations in two additional African markets during 2025 and add coverage in South Asia, where the combination of mobile penetration, healthcare infrastructure gaps, and insurance market growth creates particularly attractive conditions for the platform.
The second priority is the deepening of the platform's clinical and data capabilities. Luminary Health has accumulated a unique longitudinal health dataset across its patient population that is increasingly valuable not only for improving patient care outcomes but also for building the actuarial models needed to price insurance products appropriately for underserved populations. Investment in data science infrastructure and clinical informatics will accelerate the development of these capabilities.
The third priority is payer and institutional partnerships. The company has early relationships with several national health insurance schemes and with employers in the formal economy of its operating markets, but these relationships require dedicated business development resource and careful regulatory navigation to scale. The Series A capital will fund a team of payer relations specialists who can build out this critical part of the revenue architecture.
Looking Ahead
We are at an early stage of what we believe will be a long and significant partnership with Luminary Health's founders and with Lightspeed Venture Partners. The company faces real challenges: operating across eight countries with different regulatory environments, reimbursement structures, and cultural contexts requires organisational sophistication that is still being built. Supply of quality clinical staff is a real constraint in many of the markets the company serves. And the path from current scale to the kind of patient volumes required to build a genuinely dominant regional platform will require sustained capital investment and operational execution over many years.
But we believe the Luminary Health team has demonstrated the attributes that give us the highest level of confidence: intellectual honesty about their current limitations, a systematic approach to market selection and expansion sequencing, and a genuine commitment to clinical quality that manifests in measurable patient outcomes. These are the ingredients of a company that can navigate complexity and emerge as a lasting institution. We are proud to be invested alongside them and alongside Lightspeed Venture Partners as co-stewards of their growth.